IPM Take
Fast review is not fast access. Pancreatic cancer badly needs regulatory urgency, but urgency cannot stop at the agency door. If daraxonrasib reaches approval, the next bottleneck will be the system: RAS testing, treatment-line clarity, reimbursement, centre readiness and fair access beyond flagship hospitals.
Executive Summary
Revolution Medicines announced that EMA’s CHMP had started a phased review of daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor for pancreatic cancer. The company said daraxonrasib has EMA orphan medicinal product designation for pancreatic cancer and high-priority recognition under EMA’s Cancer Medicines Pathfinder project. It also said a rolling NDA submission to the FDA under the Commissioner’s National Priority Voucher pilot programme is nearing completion. The regulatory push is supported by positive Phase III RASolute 302 results in previously treated metastatic pancreatic ductal adenocarcinoma.
Why it matters
- Patients / advocates: Pancreatic cancer patients do not have time for slow regulatory theatre or slow access after approval.
- Regulators: Phased review signals urgency, but approval standards and post-approval evidence expectations still matter.
- Clinicians: Treatment sequencing in previously treated metastatic PDAC may change if the evidence translates into approval.
- Payers / HTA bodies: Early dialogue will be needed on eligible populations, RAS status, value and speed of reimbursement.
Pancreatic cancer has a way of exposing the cruelty of slow systems.
Revolution Medicines announced that EMA’s CHMP has begun a phased review of daraxonrasib, its investigational RAS(ON) multi-selective inhibitor. The mechanism matters, but the regulatory signal matters too. EMA is not waiting passively for a complete marketing authorisation application. It is reviewing data in phases as they become available.
That is exactly the kind of urgency pancreatic cancer deserves.
The company says the review is supported by positive Phase III RASolute 302 results in previously treated metastatic PDAC, including improvements in overall survival and progression-free survival compared with standard cytotoxic chemotherapy. It also says patients treated with daraxonrasib had delayed deterioration in cancer-related pain, global health status and quality of life.
Those are the right endpoints to be talking about in pancreatic cancer. Survival matters. Pain matters. Quality of life matters. A drug that only moves a scan but leaves patients worse off would not be enough.
But the politics of speed should not become the politics of hype.
Daraxonrasib is still investigational. A phased review is not approval. A rolling NDA is not reimbursement. Breakthrough and orphan designations do not automatically mean every eligible patient will reach the medicine quickly, or that every health system will know how to identify candidates.
The real readiness question is whether health systems can build the pathway before the approval arrives. RAS testing must be available. Treatment lines must be clear. Referral must be fast. HTA bodies must not wait until after launch to discover that pancreatic cancer moves faster than their timelines.
Pancreatic cancer is forcing regulators to move faster. Now it has to force health systems to move faster too.
